Savvy Trades and Investments

[RNsidersbuying]

NBIO .059 - SAN DIEGO, CA / ACCESSWIRE / October 7, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech" or the "Company") announces today that the Company is in the process of making significant additions to its core team in order to prepare for the initiation of key Phase One clinical trials to study the safety and efficacy of the Company's flagship drug, Pritumumab (PTB), a monoclonal antibody, for the treatment of Brain Cancer.

https://finance.yahoo.com/news/nascent-biotech-announces-key-personnel-120000609.html

The onset of this Phase 1 entails Brain Cancer studies...the separate covid-19 therapeutic & vaccine studies are all bonus to the risk taken here...